ReCode Therapeutics to Present Preclinical Data from mRNA-based Program for Cystic Fibrosis at Upcoming Virtual 2021 North American Cystic Fibrosis Conference

ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that it will present preclinical data from its mRNA-based therapeutic program for cystic fibrosis (CF) in a poster presentation at the upcoming 2021 North American Cystic Fibrosis Conference (NACFC) to be held virtually from November 2-5, 2021.

Details are as follows:

Poster: Variant-Agnostic CFTR Rescue After Aerosolized Delivery of CFTR mRNA Formulated With a SORT-LNP in Primary Human Bronchial Epithelial Cells Derived From Patients With Cystic Fibrosis

Presenter: Michael Torres, Ph.D., Vice President, R&D, ReCode Therapeutics

Poster Number: 583

Date: Wednesday, November 3, 2021

Live Poster Session: 1:10 – 1:50 p.m. ET

Dr. Torres will also present during a workshop session titled, “W05--PTC-GMS: Approaches for Delivery of Nucleotide Based Therapeutics” on Wednesday, November 3, 2021 from 11:00 a.m. – 1:00 p.m. ET.

About ReCode Therapeutics

ReCode Therapeutics (the “Company”) is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005341/en/